Unipol Assicurazioni SpA (HAM:UIPN)
€ 23.69 -0.76 (-3.11%) Market Cap: 17.28 Bil Enterprise Value: 21.44 Bil PE Ratio: 11.87 PB Ratio: 1.66 GF Score: 36/100

Q1 2026 Unipol Assicurazioni SpA Earnings Call Transcript

May 15, 2026 / 10:00AM GMT
Release Date Price: €22.27 (-0.93%)

Key Points

Positve
  • Significant improvement in technical profitability in both Life and Non-Life segments.
  • Combined ratio reached a favorable 90%, aligning with industrial plan targets.
  • Strong solvency position bolstered by a EUR1 billion restricted Tier 1 issuance and organic capital generation.
  • Bancassurance channel exhibited robust growth, exceeding 30% in the first quarter.
  • Increased contribution from coupons and dividends in investment income compared to the previous year.
Negative
  • Investment income contribution was lower by approximately EUR50 million compared to the previous year due to softer financial market performance.
  • Attritional loss ratio increased to 69% from 68% last year, reflecting a more prudential approach.
  • Health premiums showed signs of deceleration, attributed to a lack of new large contracts.
  • Expense ratios worsened in both Motor and Non-Motor segments, partly due to increased commission ratios linked to technical profitability.
  • Non-Motor growth was modest at 0.8%, impacted by a significant reduction in Marine Insurance premiums.
Operator

Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the Unipol Group first-quarter 2026 results conference call. (Operator Instructions) At this time, I would like to turn the conference over to Mr. Matteo Laterza, CEO of Unipol. Please go ahead, sir.

Matteo Laterza
Unipol Assicurazioni SpA - Chief Executive Officer, Executive Director

Thank you very much, and good morning to everyone, and thank you for connecting to this call regarding the Q1 '26. You saw the presentation and the press release. So there will not be a presentation on my side, but only a few remarks on how the quarter was. And by comparing Q1 '26 with Q1 '25, I can make only a couple of remarks. First of all, a significant improvement in the technical profitability in Life and Non-Life.

In particular, in Life, the improvement was spread in all the line of business, traditional product, but also unit-linked and patient funds. And also in Non-Life, the improvement was very important in Motor and Non-Motor. Notwithstanding, we maintained a very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot